Appili Therapeutics Inc.
APLIF
$0.026
-$0.002-7.14%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 39.80% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.80% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 39.80% | -- | |||
| SG&A Expenses | -22.42% | -20.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.89% | -18.29% | |||
| Operating Income | -27.63% | 33.44% | |||
| Income Before Tax | 84.57% | 39.07% | |||
| Income Tax Expenses | -85.62% | 236.56% | |||
| Earnings from Continuing Operations | 84.62% | 36.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 84.62% | 36.84% | |||
| EBIT | -27.63% | 33.44% | |||
| EBITDA | -27.71% | 33.49% | |||
| EPS Basic | 85.00% | 36.84% | |||
| Normalized Basic EPS | 83.33% | 38.98% | |||
| EPS Diluted | 85.00% | 36.84% | |||
| Normalized Diluted EPS | 83.33% | 38.98% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
